Therapeutic plasma exchange and HLA desensitization

12 Sep Therapeutic plasma exchange and HLA desensitization

HLA sensitization remains a significant hurdle in renal transplantation, affecting approximately one-third of the patient population on the waiting list. Despite considerable advancements over the past two decades, effective desensitization strategies are still urgently needed in clinical practice. A range of therapies, including therapeutic plasma exchange, immunotherapies targeting CD20 or CD38, proteasome inhibitors, complement inhibitors, and interleukin-6 blockade, have emerged as potential desensitization interventions. However, the outcomes from these therapies vary considerably, with each having different cost implications and profiles of adverse events.